<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02047487</url>
  </required_header>
  <id_info>
    <org_study_id>S2013-110-02</org_study_id>
    <nct_id>NCT02047487</nct_id>
  </id_info>
  <brief_title>After Induction Chemotherapy of DP Plus DDP Concurrent Radiotherapy With and Without Bevacizumab Study</brief_title>
  <official_title>Docetaxel (T), Cisplatin (P) After Induction Chemotherapy With and Without Cisplatin (P) Concurrent Radiotherapy (X) Plus Bevacizumab (B) Phase II Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open controlled multicenter phase II clinical study. The SPSS
      statistical software estimation of sample size, selection of the initial treatment of locally
      advanced head and neck squamous cell carcinoma in 120 patients, such as to achieve the
      desired results, considering expanding the clinical, according to the proportion of 1:1 were
      randomly divided into two groups, all patients were taken, docetaxel + cisplatin 2 cycles of
      induction chemotherapy 、Concurrent chemoradiotherapy（tomotherapy+cisplatin）, The experimental
      group was added with AVASTIN.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>three month after ratiotherapy</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pathological diagnosis of head and neck squamous cell carcinoma
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Men and women are not limited, requirements of ECOG0-2, age 18-70 years old, pathological
        stage III (NCCN2012), had not received radiotherapy and chemotherapy, expected to survive
        more than 3 months, the routine testing, were in the normal range, signed the informed
        consent

        Exclusion Criteria:

        Do not meet the above criteria; allergic to docetaxel and AVASTIN, or metabolic disorders;
        associated with gastrointestinal bleeding, perforation and other serious diseases; severe
        liver disease, kidney disease, respiratory disease or unable to control diabetes,
        hypertension and other chronic disease; heart disease clinical symptoms; there is
        peripheral nervous system disorders or have obvious mental disorder and disorders of the
        central nervous system; active phase &gt;CTCAE2 clinical severe infection; a history of organ
        transplantation (including bone marrow transplantation of autologous peripheral stem cell
        transplantation); pregnant, lactating women, women of childbearing age and spouse refused
        to take effective means of contraception contraception; no legal capacity, continue to
        influence medical or ethical reasons for who
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>j x li, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Haidian District Fuxing Road, Beijing No. 28 Department of radiotherapy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>z f zhao, master</last_name>
    <phone>13301253566</phone>
    <email>zhifei115@sohu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PLAGH</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PLA307</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2014</study_first_submitted>
  <study_first_submitted_qc>January 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <last_update_submitted>January 26, 2014</last_update_submitted>
  <last_update_submitted_qc>January 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>zhifei zhao</investigator_full_name>
    <investigator_title>resident physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

